Drug
Leniolisib
Leniolisib is a pharmaceutical drug with 6 clinical trials. Currently 4 active trials ongoing. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
4(67%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
3
50%
Ph phase_3
3
50%
Phase Distribution
0
Early Stage
3
Mid Stage
3
Late Stage
Phase Distribution6 total trials
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
3(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
4
trials recruiting
Total Trials
6
all time
Status Distribution
Active(4)
Completed(1)
Other(1)
Detailed Status
Active, not recruiting4
unknown1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
4
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 23 (50.0%)
Phase 33 (50.0%)
Trials by Status
active_not_recruiting467%
unknown117%
completed117%
Recent Activity
4 active trials
Showing 5 of 6
completedphase_2
Leniolisib for Immune Dysregulation in CVID
NCT06897358
active_not_recruitingphase_2
Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation
NCT06990529
active_not_recruitingphase_3
Pediatric Patients Aged 1 to 6 Years With APDS
NCT05693129
active_not_recruitingphase_3
Pediatric Patients Aged 4 to 11 Years With APDS
NCT05438407
active_not_recruitingphase_2
Leniolisib for Immune Dysregulation in PIDs
NCT06549114
Clinical Trials (6)
Showing 6 of 6 trials
NCT06897358Phase 2
Leniolisib for Immune Dysregulation in CVID
NCT06990529Phase 2
Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation
NCT05693129Phase 3
Pediatric Patients Aged 1 to 6 Years With APDS
NCT05438407Phase 3
Pediatric Patients Aged 4 to 11 Years With APDS
NCT06549114Phase 2
Leniolisib for Immune Dysregulation in PIDs
NCT06249997Phase 3
An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6